PRPO
Precipio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Precipio, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
0.00%
PRPO weight · VTI
No changes.
No changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Same SIC code · 6
Same SEC industry code: Agilent Technologies, Inc., Waters Corp, Mettler Toledo International Inc/ and 3 more; no measured co-movers for Precipio, Inc..
Same SIC code · 6
Same SEC industry code: Agilent Technologies, Inc., Waters Corp, Mettler Toledo International Inc/ and 3 more; no measured co-movers for Precipio, Inc..
Precipio, Inc.
18.00
+0.21 · +1.18%
post 19.10 +6.11%
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $1.1M | 29.19% | +81.09% |
| BlackRockindex-like | $858,058 | 21.92% | +19.41% |
| Geodeindex-like | $462,912 | 11.82% | −0.64% |
| Renaissance Technologies | $401,087 | 10.25% | −16.07% |
| Citadel | $364,319 | 9.31% | −2.66% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $1.1M | 29.19% | +81.09% |
| BlackRockindex-like | $858,058 | 21.92% | +19.41% |
| Geodeindex-like | $462,912 | 11.82% | −0.64% |
| Renaissance Technologies | $401,087 | 10.25% | −16.07% |
| Citadel | $364,319 | 9.31% | −2.66% |
+19.36%
shares held · 10 largest managers
Bull1
Bear2